Thorotrast-induced cholangiocarcinoma: case report

@article{Sahani2003ThorotrastinducedC,
  title={
Thorotrast-induced cholangiocarcinoma: case report},
  author={D. Sahani and S. R. Prasad and K. K. Tannabe and P. Hahn and P. Mueller and S. Saini},
  journal={Abdominal Imaging},
  year={2003},
  volume={28},
  pages={0072-0074}
}
AbstractThorotrast, a contrast medium used extensively before being banned in 1950s, delivers a densely ionizing, high linear energy transfer type of radiation that predisposes to malignancies. We report a case of peripheral cholangiocarcinoma and describe its computed tomographic and magnetic resonance imaging features in a patient who developed it 48 years after exposure to Thorotrast.  
Radiation-induced cholangitis with hepatocellular carcinoma.
TLDR
The case of a 45-year-old patient who had undergone upper abdominal radiotherapy for Hodgkin's disease, which was complicated years later by cholangitis with stricture of the common bile duct, and who died from carcinoma some months later is reported. Expand
Diagnosis and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma.
TLDR
In this chapter, the risk factors, clinical presentation, and management of cholangiocarcinoma are reviewed. Expand
Anaphylactoid and adverse reactions to radiocontrast agents.
  • J. Hagan
  • Medicine
  • Immunology and allergy clinics of North America
  • 2004
TLDR
This summary is intended to be a guide for the allergy and immunology specialist to direct him or her to the current literature regarding adverse reactions to traditional and less commonly used radiologic contrast agents. Expand
Distal biliary malignancy.
TLDR
Distal cholangiocarcinoma (malignancy in the common bile duct from the cystic duct to the ampulla) remains a rare diagnosis and the treatment of choice for resectable disease is pancreaticoduodenectomy and the overall 5-year survival remains 20%. Expand
Point-of-Care Clinical Guide: Cholangiocarcinoma
TLDR
Factors most commonly associated with disease development, available treatments, and anticipated outcomes for cholangiocarcinoma are discussed. Expand
Cholangiocarcinoma: Epidemiology, Risk Factors, Pathogenesis, and Diagnosis
TLDR
Carohydrate antigen 19-9 is the most commonly used tumor marker, and magnetic resonance cholangiopancreatography is the best available imaging modality for CCA. Expand
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.
TLDR
Magnetic resonance imaging/magnetic resonance cholangiopancreatography, positron emission tomography scan, endoscopic ultrasound and computed tomography scans are the most frequently used modalities for diagnosis and tumor staging. Expand
Cholangiocarcinoma Presenting as Humoral Hypercalcemia of Malignancy: A Case Report and Literature Review
TLDR
A case of hypercalcemia presenting as the first manifestation of an underlying rare variant of intrahepatic cholangiocarcinoma is reported, which led to an urgent inpatient treatment with gemcitabine/cisplatin combination chemotherapy to control the aggressive nature of the malignancy. Expand
Intrahepatic Cholangiocarcinoma
Aim: The authors give a complete overview on this disease from epidemiology to treatment. Background: Cholangiocarcinoma (CCA) is an epithelial tumor with features of cholangiocyte differentiation.Expand
Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature.
adjusted mortality rate increased from 0.07 per 100,000 in 1973 to 0.69 per 100,000 in 1997, with average age at presentation in the 7th decade of life and male-to-female ratio of 1.5. 9 ExtrahepaticExpand
...
1
2
3
4
5
...

References

SHOWING 1-8 OF 8 REFERENCES
MRI appearance of thorotrast-induced cholangiocarcinoma in a case of thorotrastosis.
The case of a 71-year-old man with thorotrastosis and a cholangiocarcinoma detected by MRI is presented, and the radiographic appearance of the cholangiocarcinoma is discussed. We concluded that MRExpand
MRI in thorotrastosis.
Magnetic resonance imaging (MRI) and computed tomography (CT) were performed in four patients with thorotrastosis. On CT scan, Thorotrast (thorium oxide) deposition was shown as high-density areas inExpand
Intrahepatic peripheral cholangiocarcinoma: CT evaluation
TLDR
In the proper clinical setting, detection of a hypodense hepatic lesion with peripheral enhancement, biliary dilatation, and contrast enhancement on delayed images are highly suggestive of peripheral intrahepatic cholangiocarcinoma. Expand
The german thorotrast study: recent results and assessment of risks.
TLDR
The German Thorotrast study comprises 2,326 patients and 1,890 controls and the cumulative risk estimate for liver cancer and hematopoietic malignancies is lower by a factor of 10 compared to the results of the Life Span Study. Expand
Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients.
TLDR
The study suggests that the MR features of intrahepatic cholangiocarcinoma are well correlated with pathologic findings, but are nonspecific. Expand
Pathomorphologic characteristics of 102 cases of thorotrast‐related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma
TLDR
Findings suggest that Th influences are more carcinogenic to epithelial cells of the bile duct and sinusoidal lining cells than hepatocytes. Expand
Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI.
TLDR
D-CT is better than D- MRI for demonstrating vascular involvement and extrahepatic invasion, and D-MRI gives more conspicuous enhancement, which can provide important information for the diagnosis of PCC. Expand
High rate of small TP53 mutations and infrequent loss of heterozygosity in malignant liver tumors associated with thorotrast: implications for alpha-particle carcinogenesis.
TLDR
The low frequency of changes in the TP53 gene in the liver tumors related to Thorotrast suggests that the genetic changes were not caused mainly by direct actions of alpha particles but rather by indirect effects that may have been due to cycles of necrosis and regeneration. Expand